AFT hits US approval target, triggers cash

AFT hits US approval target, triggers cash
Managing director Hartley Atkinson said Maxigesic was an effective alternative for the US$700 million of IV paracetamol sold each year. (Photo: supplied).
Dan Brunskill
The United States medical regulator has accepted an application for AFT Pharmaceuticals’ patented pain relief medicine, which if approved would open up a more than US$300 million market.The US Food and Drug Administration has formally received the application for Maxigesic IV, an intravenous form of AFT’s painkiller, which was filed in August this year.Filing with the FDA triggers milestone payments worth US$3.6m under a licensing deal with US partner Hikma Pharmaceuticals. This will be recognised in the first half of the current fi...

More Markets

Nvidia slump drags Wall Street and NZ sharemarket lower
Markets Market Close

Nvidia slump drags Wall Street and NZ sharemarket lower

The S&P/NZX 50 Index closed 20 points or 0.15% down at 13,419.40.

Jamie Gray 21 Nov 2025
RBNZ reopens Wellington office after asbestos mayhem
Finance

RBNZ reopens Wellington office after asbestos mayhem

Bank tight-lipped on how many staff are home-working as asbestos-hit office reopens. 

Andy Macdonald 21 Nov 2025
Oceania Healthcare extends dividend freeze
Markets

Oceania Healthcare extends dividend freeze

The retirement village operator hasn't paid a dividend since June 2023.

John Anthony 21 Nov 2025